Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Drug Control Governance: Regulatory Bodies and Their Impact

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Clinically Relevant Drug Product Specifications: Methods of Establishment

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

The Lurking Limitations of the Americans with Disabilities Act: An Introduction to the 2025-2026 National Health Law Moot Court Competition Problem.

The Journal of legal medicine·2026

Same journal

2025-2026 Southern Illinois University National Health Law Moot Court Competition.

The Journal of legal medicine·2026

Same journal

2025-2026 Southern Illinois University National Health Law Moot Court Competition: Winning Brief.

The Journal of legal medicine·2026

Same journal

Editor's Note.

The Journal of legal medicine·2026

Same journal

Risks of Improper Stimulant Prescribing With Telemedicine-Only Platforms.

The Journal of legal medicine·2026

Same journal

A Review of Medical and Legal Characteristics for Urethroplasty-Related Litigation and Medical Malpractice Cases.

The Journal of legal medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Current Challenges in Japan's Pharmaceutical Patent Regulatory Framework.

Thi Minh Hang Duong

The Journal of Legal Medicine

|June 18, 2026

Summary

This study reviews Japan

Area of Science:

Pharmaceutical Law and Regulation
Intellectual Property Rights
Healthcare Policy

Background:

The pharmaceutical sector in Japan operates under a complex regulatory framework.
Effective patent protection is crucial for driving innovation and ensuring access to medicines.
Existing legal and enforcement mechanisms face challenges impacting stakeholders.

Purpose of the Study:

To conduct a comprehensive review of Japan's pharmaceutical patent regulatory framework.
To analyze the interplay between marketing authorization, reimbursement pricing, and patent law.
To identify challenges and propose actionable recommendations for improvement.

Main Methods:

In-depth assessment of patent legislation and its application in the pharmaceutical industry.

Keywords:

Japanese healthcare law Japanese patent law Japanese pharmaceutical law patent linkage pharmaceutical antitrust

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jun 20, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Analysis of foundational legal structures, including marketing authorization and reimbursement.

Review of key judicial decisions, industry practices, and international comparative approaches.

Main Results:

Identified specific challenges within Japan's current legislative and enforcement mechanisms for pharmaceutical patents.
Highlighted the impact of these challenges on stakeholder rights and innovation.
Provided insights from international experiences to inform potential solutions.

Conclusions:

Addressing identified challenges can enhance the protection of intellectual property rights in Japan's pharmaceutical sector.
Improvements are necessary to foster innovation, improve medical access, and support the healthcare industry.
Comparative analysis suggests pathways for legislative and enforcement refinement.